## Background and Objectives: The extreme drug resistance (EDR) assay is an in vitro chemoresistance assay performed on tumor samples grown in culture and is claimed to predict drugs unlikely to produce response. Its clinical value in patients with epithelial ovarian cancer (EOC) has recently been
Correlation between Extreme Drug Resistance Assay and Response to Primary Paclitaxel and Cisplatin in Patients with Epithelial Ovarian Cancer
β Scribed by Gamal H. Eltabbakh; M.Steven Piver; Ronald E. Hempling; Fernando O. Recio; Shashikant B. Lele; David L. Marchetti; Trudy R. Baker; Leslie E. Blumenson
- Book ID
- 112247459
- Publisher
- Elsevier Science
- Year
- 1998
- Tongue
- English
- Weight
- 67 KB
- Volume
- 70
- Category
- Article
- ISSN
- 0090-8258
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract The objective of this study was to evaluate the role of an __in vitro__ drug resistance assay to platinum and taxane in the management of advanced epithelial ovarian, fallopian and primary peritoneal cancer. All patients with FIGO Stage IIIc and IV who received postoperative chemotherap
## Background and Objectives: We assessed the role of salvage chemotherapy with topotecan and cisplatin in patients with platinum-and paclitaxel-resistant advanced and recurrent ovarian or primary peritoneal cancer, based on the reported in vivo and in vitro synergism between these two drugs. Meth